Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.7K
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

243
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
243
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.5K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiviral therapy and interleukin-6 blockade associated with lower thrombotic risk in hospitalized COVID-19: a target trial emulation.

Scientific reports·2026
Same author

Randomized, Double-Blind, Placebo-Controlled Clinical Trial Assessing the Efficacy of <i>Lacticaseibacillus rhamnosus</i> CRL 1505 in Preventing Upper Respiratory Tract Infections in Healthy Adults.

Microorganisms·2026
Same author

Contribution of hepatic steatosis to subclinical atherosclerosis progression in people with HIV receiving integrase inhibitors: A 5-Year prospective cohort study.

AIDS (London, England)·2026
Same author

Point-of-care ultrasound guidance for long-acting cabotegravir-rilpivirine administration improves injection-site tolerability and preserves pharmacokinetics.

AIDS (London, England)·2025
Same author

Impact of Gluteal Injection Site on Pharmacokinetics and Tolerability of Antiretroviral Therapy with Long-Acting Cabotegravir and Rilpivirine.

AIDS patient care and STDs·2025
Same author

Virological Success With Long-Acting Cabotegravir and Rilpivirine Despite Historical Rilpivirine Resistance: A Real-World Case Series.

Open forum infectious diseases·2025

Related Experiment Video

Updated: Jun 12, 2025

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

10.9K

Gene Expression Profiles Reveal Distinct Mechanisms Driving Chronic Obstructive Pulmonary Disease Exacerbations.

Melissa Bello-Perez1,2, Eduardo García-Pachón1, Nieves Gonzalo-Jimenez1,3

  • 1Hospital General Universitario de Elche-FISABIO, 03203 Elche, Spain.

International Journal of Molecular Sciences
|January 25, 2025
PubMed
Summary

Understanding chronic obstructive pulmonary disease (COPD) exacerbations requires examining gene expression. This study reveals distinct molecular pathways and biomarkers for bacterial, viral, and unknown COPD exacerbations, crucial for personalized treatment.

Keywords:
COPDbiomarkersexacerbationgene expression profilesinflammatory responsesmicrobiomepersonalized managementtranscriptomics

More Related Videos

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
08:33

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide

Published on: December 15, 2014

11.7K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

398

Related Experiment Videos

Last Updated: Jun 12, 2025

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

10.9K
A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
08:33

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide

Published on: December 15, 2014

11.7K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

398

Area of Science:

  • Pulmonary Medicine
  • Molecular Biology
  • Microbiology

Background:

  • Chronic obstructive pulmonary disease (COPD) exacerbations significantly increase morbidity and mortality.
  • Understanding the molecular underpinnings of COPD exacerbations is critical for improved patient outcomes.
  • Current diagnostic approaches may not fully capture the heterogeneity of exacerbation triggers.

Purpose of the Study:

  • To investigate differential gene expression and biological pathways in COPD exacerbations based on sputum microbiome profiling.
  • To identify distinct molecular signatures associated with bacterial, viral, and unknown exacerbation origins.
  • To discover potential biomarkers for improved differential diagnosis and personalized management of COPD exacerbations.

Main Methods:

  • Observational study of 16 COPD patients with blood and sputum samples during exacerbations and stable states.
  • Sputum microbiota analysis using 16S rRNA sequencing and respiratory virus detection via multiplex PCR.
  • Blood transcriptomic profiling using Oxford Nanopore technology, followed by differential gene expression and pathway enrichment analyses.

Main Results:

  • Identified 768 regulated genes across exacerbation groups, with 35 linked to neutrophil activation.
  • Bacterial exacerbations activated phagocytosis and toll-like receptor signaling pathways.
  • Viral exacerbations were associated with pro-inflammatory responses and mitochondrial damage; unknown exacerbations involved protozoan defense and neutrophilic asthma pathways.
  • Discovered potential biomarkers: IFITM3/ISG15 (bacterial), DEFA3 (viral), and CD47 (unknown).

Conclusions:

  • COPD exacerbations exhibit distinct transcriptomic profiles and activated biological pathways.
  • Neutrophil-driven inflammation plays a central role across different exacerbation types.
  • Identified biomarkers can aid in differential diagnosis and personalized management strategies for COPD exacerbations.